A high‐throughput RNAi screen for detection of immune‐checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes
The success of T cell‐based cancer immunotherapy is limited by tumor's resistance against killing by cytotoxic T lymphocytes (CTLs). Tumor‐immune resistance is mediated by cell surface ligands that engage immune‐inhibitory receptors on T cells. These ligands represent potent targets for therape...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
17 February 2015
|
| In: |
EMBO molecular medicine
Year: 2015, Jahrgang: 7, Heft: 4, Pages: 450-463 |
| ISSN: | 1757-4684 |
| DOI: | 10.15252/emmm.201404414 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.15252/emmm.201404414 Verlag, kostenfrei, Volltext: http://embomolmed.embopress.org/content/7/4/450 
|
| Verfasserangaben: | Nisit Khandelwal, Marco Breinig, Tobias Speck, Tillmann Michels, Christiane Kreutzer, Antonio Sorrentino, Ashwini Kumar Sharma, Ludmila Umansky, Heinke Conrad, Isabel Poschke, Rienk Offringa, Rainer König, Helga Bernhard, Arthur Machlenkin, Michael Boutros and Philipp Beckhove |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1565606345 | ||
| 003 | DE-627 | ||
| 005 | 20230427142120.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 171122s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.15252/emmm.201404414 |2 doi | |
| 035 | |a (DE-627)1565606345 | ||
| 035 | |a (DE-576)495606340 | ||
| 035 | |a (DE-599)BSZ495606340 | ||
| 035 | |a (OCoLC)1340982485 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Khandelwal, Nisit |e VerfasserIn |0 (DE-588)1145055699 |0 (DE-627)1006484418 |0 (DE-576)495603228 |4 aut | |
| 245 | 1 | 2 | |a A high‐throughput RNAi screen for detection of immune‐checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes |c Nisit Khandelwal, Marco Breinig, Tobias Speck, Tillmann Michels, Christiane Kreutzer, Antonio Sorrentino, Ashwini Kumar Sharma, Ludmila Umansky, Heinke Conrad, Isabel Poschke, Rienk Offringa, Rainer König, Helga Bernhard, Arthur Machlenkin, Michael Boutros and Philipp Beckhove |
| 264 | 1 | |c 17 February 2015 | |
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 22.11.2017 | ||
| 520 | |a The success of T cell‐based cancer immunotherapy is limited by tumor's resistance against killing by cytotoxic T lymphocytes (CTLs). Tumor‐immune resistance is mediated by cell surface ligands that engage immune‐inhibitory receptors on T cells. These ligands represent potent targets for therapeutic inhibition. So far, only few immune‐suppressive ligands have been identified. We here describe a rapid high‐throughput siRNA‐based screening approach that allows a comprehensive identification of ligands on human cancer cells that inhibit CTL‐mediated tumor cell killing. We exemplarily demonstrate that CCR9, which is expressed in many cancers, exerts strong immune‐regulatory effects on T cell responses in multiple tumors. Unlike PDL1, which inhibits TCR signaling, CCR9 regulates STAT signaling in T cells, resulting in reduced T‐helper‐1 cytokine secretion and reduced cytotoxic capacity. Moreover, inhibition of CCR9 expression on tumor cells facilitated immunotherapy of human tumors by tumor‐specific T cells in vivo. Taken together, this method allows a rapid and comprehensive determination of immune‐modulatory genes in human tumors which, as an entity, represent the ‘immune modulatome’ of cancer. | ||
| 650 | 4 | |a cancer immunotherapy | |
| 650 | 4 | |a immune suppression | |
| 650 | 4 | |a RNAi screen | |
| 700 | 1 | |a Breinig, Marco |e VerfasserIn |0 (DE-588)141226749 |0 (DE-627)703917579 |0 (DE-576)322839637 |4 aut | |
| 700 | 1 | |a Poschke, Isabel |e VerfasserIn |0 (DE-588)1143622111 |0 (DE-627)1002893240 |0 (DE-576)495086711 |4 aut | |
| 700 | 1 | |a Offringa, Rienk |e VerfasserIn |0 (DE-588)1066807485 |0 (DE-627)817963391 |0 (DE-576)426161424 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |a European Molecular Biology Organization |t EMBO molecular medicine |d [London] : Nature Publishing Group UK, 2009 |g 7(2015), 4, Seite 450-463 |h Online-Ressource |w (DE-627)594772761 |w (DE-600)2485479-7 |w (DE-576)305355961 |x 1757-4684 |7 nnas |
| 773 | 1 | 8 | |g volume:7 |g year:2015 |g number:4 |g pages:450-463 |g extent:14 |a A high‐throughput RNAi screen for detection of immune‐checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes |
| 856 | 4 | 0 | |u http://dx.doi.org/10.15252/emmm.201404414 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://embomolmed.embopress.org/content/7/4/450 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20171122 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 1066807485 |a Offringa, Rienk |m 1066807485:Offringa, Rienk |d 910000 |d 910200 |e 910000PO1066807485 |e 910200PO1066807485 |k 0/910000/ |k 1/910000/910200/ |p 11 | ||
| 998 | |g 1143622111 |a Poschke, Isabel |m 1143622111:Poschke, Isabel |d 50000 |e 50000PP1143622111 |k 0/50000/ |p 10 | ||
| 998 | |g 141226749 |a Breinig, Marco |m 141226749:Breinig, Marco |d 60000 |e 60000PB141226749 |k 0/60000/ |p 2 | ||
| 999 | |a KXP-PPN1565606345 |e 2987934149 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 22.11.2017"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"title":[{"title":"A high‐throughput RNAi screen for detection of immune‐checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes","title_sort":"high‐throughput RNAi screen for detection of immune‐checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes"}],"relHost":[{"title":[{"title_sort":"EMBO molecular medicine","title":"EMBO molecular medicine"}],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 5. November 2022","Fortsetzung der Druck-Ausgabe"],"origin":[{"publisherPlace":"[London] ; Heidelberg ; Weinheim","dateIssuedDisp":"[2009]-","publisher":"Nature Publishing Group UK ; EMBO Press ; Wiley-VCH"}],"disp":"European Molecular Biology OrganizationEMBO molecular medicine","recId":"594772761","physDesc":[{"extent":"Online-Ressource"}],"id":{"doi":["10.1002/(ISSN)1757-4684"],"zdb":["2485479-7"],"issn":["1757-4684"],"eki":["594772761"]},"part":{"volume":"7","year":"2015","text":"7(2015), 4, Seite 450-463","extent":"14","issue":"4","pages":"450-463"},"name":{"displayForm":["European Molecular Biology Organization (EMBO)"]},"pubHistory":["Vol. 1, No. 1 (Apr 1, 2009)-"],"corporate":[{"display":"European Molecular Biology Organization","role":"aut"}]}],"person":[{"family":"Khandelwal","role":"aut","given":"Nisit","display":"Khandelwal, Nisit"},{"display":"Breinig, Marco","given":"Marco","role":"aut","family":"Breinig"},{"display":"Poschke, Isabel","role":"aut","given":"Isabel","family":"Poschke"},{"family":"Offringa","given":"Rienk","role":"aut","display":"Offringa, Rienk"}],"origin":[{"dateIssuedKey":"2015","dateIssuedDisp":"17 February 2015"}],"physDesc":[{"extent":"14 S."}],"recId":"1565606345","id":{"eki":["1565606345"],"doi":["10.15252/emmm.201404414"]},"name":{"displayForm":["Nisit Khandelwal, Marco Breinig, Tobias Speck, Tillmann Michels, Christiane Kreutzer, Antonio Sorrentino, Ashwini Kumar Sharma, Ludmila Umansky, Heinke Conrad, Isabel Poschke, Rienk Offringa, Rainer König, Helga Bernhard, Arthur Machlenkin, Michael Boutros and Philipp Beckhove"]}} | ||
| SRT | |a KHANDELWALHIGHTHROUG1720 | ||